PharmAla Biotech Holdings Inc

MDXX-class molecules producer PharmAla Biotech Holdings Inc. and natural psychedelics developer Filament Health Corp's (OTCQB: FLHLF) partnership is seeing the release of GMP-compliant MDMA capsules for distribution to clinical trials and authorized patients in Canada and worldwide....

Filament’s Psilocybin, Tested On Mild Cognitive Impairment By CAMH Clinical-stage natural psychedelic drug development company Filament Health Corp. (OTCQB: FLHLF) has inked a second supply deal with Canada-based Centre for Addiction and Mental Health (CAMH) concerning its botanical...

Next-gen psychedelics producers Mindset Pharma Inc. (OTCQB: MSSTF) and PharmAla Biotech Holdings Inc. have entered into an exclusive sales agreement making PharmAla the sole global reseller of Mindset’s current Good Manufacturing Process (cGMP) psilocybin to licensed clinical researchers....

PharmAla Biotech Holdings Inc, the biotech company producing MDXX class molecules has released a large-scale batch of its proprietary MDMA API, “Laneo,” becoming the first publicly-traded venture to produce the drug within Good Manufacturing Processes (GMP) in such a major...

A new deal has been signed between PharmAla Biotech Holdings Inc. (CSE: MDMA) and InterVivo Solutions for GMP MDMA and engineering MDMA supply towards research on its impact on neuropsychiatric and neurological diseases. The agreement entails that PharmAla will provide both its clinical-...